Clinical Trials
7 trialsNCT00422201 2019-10-11
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
HRA Pharma
Phase 2 Terminated
NCT03210324 2019-08-07
A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy
China Resources Zizhu Pharmaceutical Co., Ltd.
Phase 4 Terminated
NCT02014337 2018-01-17
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Corcept Therapeutics
Phase 1 Completed
NCT00936741 2014-04-02
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT01371565 2014-03-18
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT00569582 2013-08-22
SEISMIC
Corcept Therapeutics
Phase 3 Completed
NCT00881140 2012-12-19
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
BioPro Medical Ltd
Phase 2 Completed